X0206 3 2016-10-26 0 0001679082 Myovant Sciences Ltd. MYOV 0001290166 QVT Associates GP LLC 1177 AVENUE OF THE AMERICAS, 9TH FLOOR NEW YORK NY 10036 1 0 1 1 See remarks 0001543904 QVT Fund V LP 190 ELGIN AVENUE GEORGE TOWN, GRAND CAYMAN E9 KY1-9005 CAYMAN ISLANDS 1 0 1 1 See remarks Common Shares, $0.00001 par value per share 37231342 I See Explanation of Responses QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Fund V LP and QVT Associates GP LLC, the general partner of QVT Fund V LP (collectively, "QVT"), may be deemed to have beneficial ownership over the 37,231,342 Common Shares held by Roivant Sciences Ltd. ("Roivant") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares directly held by Roivant by virtue of governance arrangements in Roivant's bye-laws, namely, the appointment of one or more independent directors (within the meaning of that term under Roivant's bye-laws) to Roivant's board of directors. The filing of this statement shall not be deemed an admission that QVT or Dr. Keith Manchester is the beneficial owner of the securities reported herein for the purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. (continued from Footnote 1) Each of QVT and Dr. Manchester expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. QVT may be deemed to be a director by virtue of the fact that Dr. Manchester (the Head of Life Sciences and a Portfolio Manager at QVT Financial LP, as well as a director of Roivant), on behalf of Roivant, currently serves on the board of directors of the issuer. /s/ Tracy Fu 2016-10-26